Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The efficacy of these drugs in weight loss has led to an increased demand
What the tentative approval confirms: The generic product meets FDA standards for safety, quality, and efficacy The application has cleared scientific and regulatory review The only remaining barrier is Novo Nordisk's residual patent protections What it does not mean: The product can be sold or prescribed today in the US Prices will drop immediately Compounded semaglutide remains a legal alternative (it does not see below) The key legal event to watch is patent litigation
Ivm Health focuses not only on achieving weight loss but also on maintaining it long-term
Copayments are expected to be high
US$ 21.68
US$ 23.34
US$ 26.65
US$ 20.97
US$ 21.18
US$ 26.37
US$ 24.17
US$ 29.16
